Dietary Fructose: a Metabolic Switch in Pediatric Obesity-related Disease. (EO2022)

April 11, 2024 updated by: Flavia Prodam, Azienda Ospedaliero Universitaria Maggiore della Carita

Evaluation of Liver and Osteo-metabolic Complications Related to the Consumption of Fructose in a Cohort of Overweight and Obese Children and Adolescents.

The increase in childhood obesity is a multifactorial phenomenon influenced by dietary patterns, commercial factors, and social determinants; it has long-term consequences for both individual health and society as a whole. Despite recommendations for maintaining good health throughout life and promoting the Mediterranean Diet, due to the increased availability of ultra-processed and more appealing foods, children and adolescents are shifting towards a "Western" diet. One in four children consumes sugary and carbonated drinks every day, which contributes to a high intake of fructose in the diet, while fruits and vegetables are consumed less, and legumes are included in the diet of only 38% of children less than once a week.

Fructose is a monosaccharide naturally found in fruits, vegetables, and honey; due to its high sweetness and taste-enhancing properties, fructose is widely used in the food industry. High-fructose corn syrup, in particular, is one of the most widely used ingredients in the production of soft drinks, jams, breakfast cereals, and bakery products. Non-alcoholic fatty liver disease (NAFLD), now also called metabolic dysfunction-associated fatty liver disease (MAFLD), is considered the hepatic manifestation of metabolic syndrome and currently represents the most common chronic liver disease in pediatric age in Western countries. Recent studies suggest that fructose consumption is implicated in the development of NAFLD both directly by providing metabolites that can be used for triglyceride and free fatty acid synthesis, and indirectly through increased uric acid production. High-fructose foods also appear to be a risk factor for bone loss. Numerous studies conducted over the past 25 years, during which fructose consumption has exponentially increased, have shown that this sweetener tends to increase the incidence of fractures and osteoarthritis and decrease bone mineral density (BMD) and new bone tissue deposition.

The objective of this study is to understand the effect of fructose on the molecular events that contribute to the evolution of the pediatric age, and its effective relationship with the onset of liver and osteoarticular complications in this population. Understanding the mechanisms of fructose regulation and its effects on the body could be an important target to address the clinical and social problems arising from its spread in children.

Study Overview

Status

Recruiting

Conditions

Detailed Description

At the time of recruitment, patients referred to the Endocrinology Outpatient Clinic of the AOU (Azienda Ospedaliera Universitaria) Maggiore della Carità in Novara, the Transition Endocrinology Outpatient Clinic of the Endocrinology SCDU (Struttura Complessa a Direzione Universitaria), and the Pediatric Endocrinology Outpatient Clinic "B. Trambusti" of the Giovanni XXIII Pediatric Hospital, will undergo:

Questionnaires to assess the quantity of fructose intake through diet:

  • KIDMED (quality index for children and adolescents) questionnaire to evaluate adherence to the Mediterranean diet in children/adolescents.
  • IDEFICS (Identification and preven- tion of Dietary- and lifestyle- induced health EFfects In Children and infantS) questionnaire to assess food frequency in children.
  • 24-hour recall questionnaire to gather information about meals consumed in the previous 24 hours. Macronutrient quantities will be obtained using dedicated software, "Professional Diet Therapy Software Dietosystem" from DSMedica(industry supplying the software). The questionnaire includes specific questions and figures to identify food portions and relate them to the quantity of fructose consumed.
  • Calculation of the Dietary Inflammatory Index (DII) through a list of foods. This parameter allows for the determination of how much a dietary pattern promotes the synthesis of pro-inflammatory molecules.
  • Sociological questionnaire prepared ad hoc by Unit 3 to assess dietary habits and fructose intake in relation to the family's socioeconomic status.

Anamnestic evaluation:

  • The mother of the patient will be asked for gestational age, mode of delivery, and the child's birth anthropometric data.
  • Recording of current pharmacological therapy (if present).

Instrumental evaluation:

  • Quantitative and qualitative analysis of bone composition using quantitative ultrasound (QUS). This tool provides various parameters related to bone composition, specifically speed of sound (SOS) for bone density evaluation, broadband ultrasound attenuation (BUA) for trabecular structure evaluation, ultrasound peak amplitude for trabecular size evaluation, number of peaks for connectivity evaluation of the mineralized matrix structure, and energy and amplitude of fast waves for elasticity evaluation.
  • Abdominal ultrasound (US) to assess hepatic steatosis, perivisceral and subcutaneous fat. The presence of hepatic steatosis (NAFLD) will be classified from stage 1 to stage 3 according to the literature.

Clinical-auxological evaluation:

  • Anthropometric measurements including weight, height, and BMI according to STANDARD DEVIATION SCORE (SDS).
  • Waist and hip circumference measurements.
  • Measurement of blood pressure and heart rate.
  • Analysis of body composition through bioimpedance analysis (BIA).

Expected results With this study, the investigators expect to acquire new knowledge about the effect of fructose on the onset of obesity-associated liver disease (NAFLD) and bone metabolism, by identifying new biological, immunological, and omics markers that can be studied in the future as disease targets in the pediatric population. Furthermore, due to scientific and sociological interest, this study aims to identify sociodemographic and cultural determinants related to fructose intake, which will be useful for creating preventive campaigns aimed at promoting a healthy lifestyle. This includes changing dietary habits to encourage a healthy diet and reducing obesity in the population.

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Novara, Italy, 28100
        • Recruiting
        • SCDU Pediatria, AOU Ospedale Maggiore della Carità
        • Contact:
          • Flavia Prodam, MD PHD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

N/A

Sampling Method

Probability Sample

Study Population

100 pediatric patients with overweight and obesity

Description

Inclusion Criteria:

  • Children and adolescents of both sexes aged 3-6 years and 12-16 years, as interest groups for the assessment of hepatic steatosis induced by fructose consumption.
  • Children with overweight (defined by BMI > 97 year old percentile for children under 5 years old; and BMI >85 year old percentile for children over 5 years old) or obesity (defined by BMI > 99 percentile for children under 5 years of age; and BMI > 97 percentile for children over 5 years of age)

Exclusion Criteria:

  • Children and adolescents not in that age group:
  • Children and adolescents with different liver diseases of NAFLD, as it is the interest of the study
  • Children and adolescents with genetic obesity or secondary obesity since the interest of the study is obesity caused by excessive calorie intake
  • Children and adolescents included in diet-therapy regimen with different dietary styles from the Mediterranean or Western diet (example ketogenic diet, FoadMap (fermentable oligosaccharides, disaccharides, monosaccharides and polyols) diet, vegan/vegetarian diet) to avoid bias in the interpretation of the microbial signature (the microbial signature of the Western and Mediterranean diet is known in the literature);

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
assessment of fructose intake with questionnaires
Time Frame: evaluation of fructose intake through study completion, an average of 1 year
assessment of fructose intake in preschool children and adolescent with obesity or overweight, using questionnaires with multiple answers
evaluation of fructose intake through study completion, an average of 1 year
correlation of fructose consumption with hepatic complications, detected trough echo-abdomen and blood analysis
Time Frame: assessment of fructose intake in correlation with hepatic complications through study completion, an average of 1 year
assessment of fructose intake in correlation with hepatic complications using echo-abdomen and blood analysis as detection methods
assessment of fructose intake in correlation with hepatic complications through study completion, an average of 1 year
Correlation of fructose consumption with bone metabolism, detected through QUS
Time Frame: assessment of fructose intake in correlation with bone metabolism through study completion, an average of 1 year
assessment of fructose intake in correlation with bone metabolism, using QUS as detection method
assessment of fructose intake in correlation with bone metabolism through study completion, an average of 1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Characterization of the concentration of intestinal microorganisms
Time Frame: Evaluation of microbiota after 12 months
Characterization of microorganisms present in the gastrointestinal tract and their microbial activity
Evaluation of microbiota after 12 months
Evaluate sociodemographic and cultural determinants with questionnaires ( questions with multiple answers)
Time Frame: Evaluation of sociodemographic data after 12 months
Evaluate sociodemographic and cultural determinants, and differences between Northern and Southern Italy through the use of questionnaires. Assessment scales will not be used, but will be a collection of data evaluated in a descriptive manner. There are no maximum and minimum, but what we will get from the questionnaires will be a descriptive overview of the population in Italy.
Evaluation of sociodemographic data after 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Flavia Prodam, MD PHD, Aou Maggiore Della Carita

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 4, 2024

Primary Completion (Estimated)

March 5, 2025

Study Completion (Estimated)

March 2, 2026

Study Registration Dates

First Submitted

February 12, 2024

First Submitted That Met QC Criteria

April 11, 2024

First Posted (Actual)

April 15, 2024

Study Record Updates

Last Update Posted (Actual)

April 15, 2024

Last Update Submitted That Met QC Criteria

April 11, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • CE209/2023

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pediatric Obesity

3
Subscribe